Samyang Biopharm Submits Annual Conglomerate Disclosure: Reveals Stable Financials and Concentrated Ownership Structure, Limited Impact on Shareholder Value
Financial Status: Total assets 339.3B KRW, total liabilities 104.5B KRW, total equity 234.7B KRW, debt ratio 44.54%, indicating stable financial structure
Earnings: Revenue 28.6B KRW, operating profit 2.7B KRW, net income 2.2B KRW
Governance: Controlling shareholder group (Kim Yoon and related parties) holds 52.47% stake, ensuring stable management control; other shareholders 47.53%
Related Party Transactions: Sales to domestic affiliates 90M KRW (0.31% of revenue), purchases from affiliates 5M KRW (0.04% of purchases), insignificant
Other: Treasury shares 5,850 (0.08%), no separate shareholder return policy
[AI Summary]This disclosure is a routine annual filing for a conglomerate affiliate. The company shows stable financials and governance, but no significant catalysts exist, implying a neutral impact on stock price.
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]